The multiplicity of action of cannabinoids

Implications for treating neurodegeneration

Aoife Gowran, Janis Noonan, Veronica A. Campbell

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The cannabinoid (CB) system is widespread in the central nervous system and is crucial for controlling a range of neurophysiological processes such as pain, appetite, and cognition. The endogenous CB molecules, anandamide, and 2-arachidonoyl glycerol, interact with the G-protein coupled CB receptors, CB 1 and CB 2. These receptors are also targets for the phytocannabinoids isolated from the cannabis plant and synthetic CB receptor ligands. The CB system is emerging as a key regulator of neuronal cell fate and is capable of conferring neuroprotection by the direct engagement of prosurvival pathways and the control of neurogenesis. Many neurological conditions feature a neurodegenerative component that is associated with excitotoxicity, oxidative stress, and neuroinflammation, and certain CB molecules have been demonstrated to inhibit these events to halt the progression of neurodegeneration. Such properties are attractive in the development of new strategies to treat neurodegenerative conditions of diverse etiology, such as Alzheimer's disease, multiple sclerosis, and cerebral ischemia. This article will discuss the experimental and clinical evidence supporting a potential role for CB-based therapies in the treatment of certain neurological diseases that feature a neurodegenerative component.

Original languageEnglish
Pages (from-to)637-644
Number of pages8
JournalCNS Neuroscience and Therapeutics
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Cannabinoids
Cannabinoid Receptors
Artificial Receptors
Neurogenesis
Appetite
Cannabis
G-Protein-Coupled Receptors
Brain Ischemia
Cognition
Multiple Sclerosis
Alzheimer Disease
Oxidative Stress
Central Nervous System
Ligands
Pain
Therapeutics

Keywords

  • Alzheimer's disease
  • Cannabinoid
  • Cerebral ischemia
  • Multiple sclerosis
  • Neurodegeneration
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Physiology (medical)
  • Psychiatry and Mental health
  • Pharmacology

Cite this

The multiplicity of action of cannabinoids : Implications for treating neurodegeneration. / Gowran, Aoife; Noonan, Janis; Campbell, Veronica A.

In: CNS Neuroscience and Therapeutics, Vol. 17, No. 6, 12.2011, p. 637-644.

Research output: Contribution to journalArticle

@article{7e04a1eb1c134d908ccc45907e44a59f,
title = "The multiplicity of action of cannabinoids: Implications for treating neurodegeneration",
abstract = "The cannabinoid (CB) system is widespread in the central nervous system and is crucial for controlling a range of neurophysiological processes such as pain, appetite, and cognition. The endogenous CB molecules, anandamide, and 2-arachidonoyl glycerol, interact with the G-protein coupled CB receptors, CB 1 and CB 2. These receptors are also targets for the phytocannabinoids isolated from the cannabis plant and synthetic CB receptor ligands. The CB system is emerging as a key regulator of neuronal cell fate and is capable of conferring neuroprotection by the direct engagement of prosurvival pathways and the control of neurogenesis. Many neurological conditions feature a neurodegenerative component that is associated with excitotoxicity, oxidative stress, and neuroinflammation, and certain CB molecules have been demonstrated to inhibit these events to halt the progression of neurodegeneration. Such properties are attractive in the development of new strategies to treat neurodegenerative conditions of diverse etiology, such as Alzheimer's disease, multiple sclerosis, and cerebral ischemia. This article will discuss the experimental and clinical evidence supporting a potential role for CB-based therapies in the treatment of certain neurological diseases that feature a neurodegenerative component.",
keywords = "Alzheimer's disease, Cannabinoid, Cerebral ischemia, Multiple sclerosis, Neurodegeneration, Parkinson's disease",
author = "Aoife Gowran and Janis Noonan and Campbell, {Veronica A.}",
year = "2011",
month = "12",
doi = "10.1111/j.1755-5949.2010.00195.x",
language = "English",
volume = "17",
pages = "637--644",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The multiplicity of action of cannabinoids

T2 - Implications for treating neurodegeneration

AU - Gowran, Aoife

AU - Noonan, Janis

AU - Campbell, Veronica A.

PY - 2011/12

Y1 - 2011/12

N2 - The cannabinoid (CB) system is widespread in the central nervous system and is crucial for controlling a range of neurophysiological processes such as pain, appetite, and cognition. The endogenous CB molecules, anandamide, and 2-arachidonoyl glycerol, interact with the G-protein coupled CB receptors, CB 1 and CB 2. These receptors are also targets for the phytocannabinoids isolated from the cannabis plant and synthetic CB receptor ligands. The CB system is emerging as a key regulator of neuronal cell fate and is capable of conferring neuroprotection by the direct engagement of prosurvival pathways and the control of neurogenesis. Many neurological conditions feature a neurodegenerative component that is associated with excitotoxicity, oxidative stress, and neuroinflammation, and certain CB molecules have been demonstrated to inhibit these events to halt the progression of neurodegeneration. Such properties are attractive in the development of new strategies to treat neurodegenerative conditions of diverse etiology, such as Alzheimer's disease, multiple sclerosis, and cerebral ischemia. This article will discuss the experimental and clinical evidence supporting a potential role for CB-based therapies in the treatment of certain neurological diseases that feature a neurodegenerative component.

AB - The cannabinoid (CB) system is widespread in the central nervous system and is crucial for controlling a range of neurophysiological processes such as pain, appetite, and cognition. The endogenous CB molecules, anandamide, and 2-arachidonoyl glycerol, interact with the G-protein coupled CB receptors, CB 1 and CB 2. These receptors are also targets for the phytocannabinoids isolated from the cannabis plant and synthetic CB receptor ligands. The CB system is emerging as a key regulator of neuronal cell fate and is capable of conferring neuroprotection by the direct engagement of prosurvival pathways and the control of neurogenesis. Many neurological conditions feature a neurodegenerative component that is associated with excitotoxicity, oxidative stress, and neuroinflammation, and certain CB molecules have been demonstrated to inhibit these events to halt the progression of neurodegeneration. Such properties are attractive in the development of new strategies to treat neurodegenerative conditions of diverse etiology, such as Alzheimer's disease, multiple sclerosis, and cerebral ischemia. This article will discuss the experimental and clinical evidence supporting a potential role for CB-based therapies in the treatment of certain neurological diseases that feature a neurodegenerative component.

KW - Alzheimer's disease

KW - Cannabinoid

KW - Cerebral ischemia

KW - Multiple sclerosis

KW - Neurodegeneration

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=79952536002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952536002&partnerID=8YFLogxK

U2 - 10.1111/j.1755-5949.2010.00195.x

DO - 10.1111/j.1755-5949.2010.00195.x

M3 - Article

VL - 17

SP - 637

EP - 644

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 6

ER -